Moderna Delivers Strong Q1 2026 Performance: Revenue Growth, Cost Reduction, and Pipeline Advancements
Moderna, a leading biotechnology company, reported a remarkable first quarter of 2026, showcasing significant revenue growth, cost reduction efforts, and notable advancements in its pipeline.
The company's revenues surged to $0.4 billion year-over-year, primarily driven by the execution of its long-term strategic partnership with the U.K. government. This strong Q1 performance solidifies Moderna's commitment to delivering on its 2026 growth objectives, with a reiteration of up to 10% growth for the year.
Moderna's financial discipline was evident in its ability to maintain a strong balance sheet, ending the quarter with $7.5 billion in cash and investments. The company's cost reduction efforts continued to yield impressive results, with a 26% year-over-year reduction in adjusted cash costs in Q1, excluding litigation settlement. This performance keeps Moderna on track to achieve its full-year objective of approximately $4.2 billion in adjusted cash cost.
Moderna's commercial portfolio and pipeline also made significant strides in the first quarter. The company achieved a major milestone with the approval of mCOMBRIAX, a flu plus COVID combo vaccine, in the European Union. This marks Moderna's fourth approved product, making it the first flu plus COVID combo vaccine approved worldwide.
Additionally, Spikevax secured approval in the European Union, and mRNA-1010 was assigned a PDUFA date of August 5th in the U.S., paving the way for further growth drivers. In oncology, Moderna initiated a new phase III clinical trial for intismeran in non-small cell lung cancer, marking its first phase III clinical trial evaluating intismeran in a monotherapy arm in patients with early-stage disease.
Stéphane Bancel, Moderna's CEO, expressed pride in the team's performance and highlighted the company's commitment to innovation. "This is exactly what Moderna stands for," he said. "We're bringing important innovation to patients."
Jamey Mock, CFO, provided further insights into Moderna's financial performance, noting a $300 million increase in revenue versus the prior year, with international markets contributing approximately 80% of total revenue.
These results demonstrate Moderna's continued growth and momentum as it advances its pipeline and commercial portfolio. The company's commitment to delivering on its objectives is evident in its strong financial discipline and ongoing efforts to drive cost reduction and innovation."
